Navitoclax
Idiopathic Pulmonary Fibrosis · Senolytics
Clinical trials
1
Mechanism
Senolytics
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Developer
Multiple centers
Overview
More potent senolytic. Dose-limited by platelet apoptosis. Navitoclax + nintedanib combination under evaluation.
Navitoclax clinical trials
Explore related
Medical disclaimer. This page summarizes research about Navitoclax for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.